November 18, 2026
Health news, explained with evidence
LIVE

FDA Approves New Oral Treatment Combination for Advanced Breast Cancer With ESR1 Mutations

❤️ Conditions & Care 2 min read 👁 2

Federal regulators have approved a new once-daily pill combination for adults with advanced hormone receptor-positive breast cancer that has progressed despite previous hormone treatments.

FDA Approves New Oral Treatment Combination for Advanced Breast Cancer With ESR1 Mutations❤️Conditions & Care

Photo: Medical Xpress

Key points

  • FDA approved giredestrant combined with everolimus for specific advanced breast cancer cases.
  • Targets patients with estrogen receptor-positive, HER2-negative tumors carrying ESR1 mutations.
  • Clinical trial showed a median progression-free survival of 10 months compared to 5.5 months for standard care.

The U.S. Food and Drug Administration (FDA) has granted approval for giredestrant, marketed as Wilserdly, to be used alongside the cancer drug everolimus. This therapeutic pairing is authorized specifically for adults dealing with estrogen receptor-positive, HER2-negative breast cancer that has advanced into surrounding tissue or metastasized to other regions of the body. Over time, a significant portion of these tumors develop specific gene modifications known as ESR1 mutations, which allow them to evade standard hormone therapies. The approval applies exclusively to patients whose tumors carry this particular mutation and whose disease has worsened following prior endocrine treatments.

To identify eligible individuals, federal regulators simultaneously authorized a blood test called FoundationOne Liquid CDx, which detects circulating tumor DNA in the bloodstream. Giredestrant functions by binding to estrogen receptors on malignant cells to block the hormone and prompt receptor degradation, while everolimus inhibits a distinct pathway utilized by cancer cells for proliferation. The regulatory decision stems from a clinical trial involving 373 adults, including 207 participants with ESR1 mutations, where those receiving giredestrant achieved a median progression-free survival of 10 months compared to 5.5 months for patients receiving standard hormone therapy. Tumor shrinkage was observed in 27 percent of the giredestrant cohort, contrasted with 14 percent in the comparison group, though researchers noted it remains too early to determine if the regimen improves overall survival rates.

What to know: The recommended dosage is 30 milligrams daily, and reported side effects include fatigue, nausea, rash, diarrhea, and inflammation in mouth or lung tissues, alongside warnings regarding bradycardia and risks to developing fetuses. Patients should consult their healthcare provider to discuss personal treatment decisions and options.

Source Medical Xpress — medicalxpress.com/news/2026-11-pill-combo-breast-cancer-hormone.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.